- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Most Listened-to Podcast Episodes of 2019
During 2019, The Center for Biosimilars® provided interviews and discussions with key opinion leaders on our podcast to discuss various issues affecting biosimilars. From patent issues to the arrival of oncology biosimilars, here is a look at our top 5 podcast episodes from 2019.
During 2019, The Center for Biosimilars® provided interviews and discussions with key opinion leaders on our podcast, “Not So Different,” to discuss various issues affecting biosimilars. From patent issues to the arrival of oncology biosimilars, here is a look at our top 5 podcast episodes from 2019.
5. "What's Holding Back Biosimilars? It May Not Be Pay-for-Delay Deals
Pay-for-delay issues were big news on Capitol Hill, and some experts questioned whether these kinds of settlements are really at the heart of delayed biosimilar competition. Might there be alternative ways to think about, and fix, the problem? On this episode, we spoke with 2 such experts, Imron Aly, JD, and Joel Wallace, JD. Both are partners at Schiff Hardin LLP and have extensive experience with Hatch-Waxman and biosimilars intellectual property issues.
4. A Look Ahead to Biosimilar Insulin
2020 will bring the transition of insulin to regulation as biologics. On this episode, we spoke with one of the experts who testified at a FDA public hearing about biosimilar insulins, which happened amid growing concern about the skyrocketing cost of insulin in the United States. Steven Lucio, PharmD, BCPS, associate vice president of clinical solutions and pharmacy program development at Vizient, shared his thoughts with us on biosimilar insulins, interchangeability, biosimilar suffixes, and what milestones lie ahead as the United States approaches the transition.
3. Is It Time to Give Up on Biosimilars?
It’s no secret that the biosimilars market in the United States has been off to a sluggish start. In fact, former FDA Commissioner Scott Gottlieb, MD, went so far as to call the market anemic. On this episode, we talked with Mark Trusheim, MS, one of the authors of a proposal to do away with the US biosimilars market altogether. Trusheim, a biopharmaceuticals consultant, is also the strategic director of the NEWDIGS program at the Massachusetts Institute of Technology (MIT) Center for Biomedical innovation and a visiting scientist in applied economics at MIT’s Sloan School of Management.
2. Where Are We Headed With Oncology Biosimilars? Vizient Weighs In
In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs. We spoke once again with Vizient’s Steven Lucio, PharmD, BCPS, on how oncology biosimilars are poised to make an impact.
1. What Have We Learned So Far About US Oncology Biosimilars?
Among the biggest biosimilars news of this year was the launch of the first 2 anticancer biosimilars. On this episode, we talked with an expert who's sharing her insight into these developments in the oncology space. Christina Corridon, MPH, MBA, is a principal at the professional services firm ZS Associates, where she is a leader in ZS' oncology practice and leads their biosimilars vertical. She joined us to talk about the state of play in the US biosimilars market, what we can learn from ongoing experience, and how sustainable the US market for biosimilars may be today.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.
